HPHiral D. Parekh

Hiral D. Parekh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiral D. Parekh has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches

    by Aaron J Franke, William Paul Skelton, Jason S Starr, Hiral Parekh, James J Lee, Michael J Overman, Carmen Allegra, Thomas J George

    Colorectal cancer (CRC) remains a leading cause of cancer-related deaths in the United States. Although immunotherapy has dramatically changed the landscape of treatment for many advanced cancers, the benefit in CRC has thus far been limited to patients with microsatellite instability high (MSI-H):DNA mismatch repair–deficient (dMMR) tumors. Recent studies in the refractory CRC setting have led to US Food and Drug Administration approvals for pembrolizumab as well as nivolumab (with or without ipilimumab) for tumors harboring an MSI-H:dMMR molecular profile. Several randomized controlled trials are underway to move immunotherapy into the frontline for metastatic cancer (with or without chemotherapy) and the adjuvant setting. Awareness of these studies is critical given the relatively low incidence (approximately 3%–5%) of MSI-H:dMMR in advanced or metastatic CRC to support study completion, because the results could be potentially practice changing. The real challenge in this disease is related to demonstrating the benefit of immunotherapy for the vast majority of patients with CRC not harboring MSI-H:dMMR. Given the rapid pace of scientific changes, this article provides a narrative review regarding the current landscape of immunotherapy for CRC. Particular attention is paid to the currently available data that inform today’s clinical practice along with upcoming randomized controlled trials that may soon dramatically change the treatment landscape for CRC.


  • Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies

    by Nils Kroeger, Haoran Li, Guillermo De Velasco, Frede Donskov, Hao-Wen Sim, Viktoria Stühler, J. Connor Wells, Igor Stukalin, Johannes Heide, Jens Bedke, et al.


  • Final results from a phase II study of 5-fluorouracil, oxaliplatin, and dasatinib (FOLFOX-D) in previously untreated metastatic pancreatic adenocarcinoma.

    by Thomas J. George, Jason Scott Starr, Hiral D. Parekh, Alison Marguerite Ivey, Susan P. McGorray, Yu Wang, Long H. Dang, Karen Colleen Daily, Carmen Joseph Allegra, David L. DeRemer, et al.

    4124 Background: Systemic chemotherapy for pancreatic adenocarcinoma (PCa) improves survival but most targeted agents have consistently failed to demonstrate clinical benefits. Src is overexpressed in PCa and promotes an aggressive cancer phenotype. Dasatinib (D) is an oral multi-tyrosine kinase inhibitor (TKI) affecting tumor proliferation through inhibition of Src, Bcr-Abl, CKit and other pathways. Inhibition of Src is associated with biologic modifications favorably modifying the PCa phenotype and has synergy with restoring inherent chemosensitivity. Src inhibition can also increase oxaliplatin activity and modulate Tcell responses. The addition of D to the well-established backbone of FOLFOX represents a multifaceted line of scientific investigation. Methods: This phase II trial is to determine activity and toxicity of FOLFOX + D in previously untreated metastatic PCa. Pts must have at least 1 RECIST measurable target lesion, ECOG PS 0-2, normal QTc and adequate organ function. Treatment is standard q14d cycles of mFOLFOX6 with continuous D (150mg PO daily). Tumor assessments occur q8w. Endpoints are PFS (primary), objective and biochemical response rates, clinical benefit rate, freedom from metastases, overall survival (OS), toxicity, and quality of life. Exploratory tissue, CTC and serum analyses to identify predictors of response are planned. Sample size is based on a 50% improved median PFS from 4 (historical) to 6 mo. Results: 42 of 44 enrolled pts are evaluable. Baseline demographics are in Table 1. Median PFS was 4.0 mo (95% CI 2.3-8.5; range 0.1-43.3) and OS was 10.6 mo (95% CI 6.9-12.7; range 0.1-47.9). RR was 24% with clinical benefit rate (CR + PR + SD) of 60%. 10 pts (24%) were on active therapy more than a year with a few long term exceptional responders. Toxicity has been previously reported. Molecular profiling of Src expression and circulating biomarkers is ongoing. Conclusion: Addition of D to FOLFOX failed to significantly improve PFS in an unselected cohort of PCa pts. Toxicity was manageable. Analysis of Src expression in exceptional responders is ongoing. Clinical trial information: NCT01652976.


  • Differences in the characteristics of younger and older MSI-H colorectal cancer (CRC) as determined by universal reflex testing.

    by Aaron J Franke, William Paul Skelton, Maira Gaffar, Forat Lutfi, Samantha Welniak, Michael Feely, Jason Scott Starr, Hiral D. Parekh, Atif Iqbal, Sanda Tan, et al.

    3593 Background: DNA mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) CRC is found in ~15% of early stage and ~5% of metastatic disease. Universal or reflex testing to identify dMMR/MSI-H has been proposed. The CRC incidence in young patients (pts) is also rising with unclear etiology. We present a large, single-institutional database of universal reflex dMMR/MSI-H testing in CRC comparing clinicopathologic and molecular profiles of younger (≤50) and older ( > 50) pts. Methods: For all CRC pts diagnosed at University of Florida between 2009-2017, reflex somatic testing for dMMR by IHC (MLH1, PMS2, MSH2, MSH6), MSI by PCR (Promega MSI kit) and NGS was performed with appropriate positive and negative controls. IHC protein loss was confirmed by second GI pathologist. Equivocal IHC results triggered MSI testing. Review of associated clinical EMR data was retrospectively performed and analysis conducted with student's t-test. Study was IRB approved. Results: 375 pts were analyzed by ≤50yo (n = 80; median age 44, range 17-50) or > 50yo (n = 295; median age 66, range 51-98). There was 100% concordance of MMR and MSI of all patient samples. dMMR/MSI-H incidence was 14% (11/80) in pts ≤50, compared to 22% (64/295) in pts > 50 (p < 0.001). For stage IV CRC, dMMR/MSI-H incidence was 4% vs. 13% (p = 0.003) between the age groups. Younger pts presented with more advanced disease (36% Stage III, 36% Stage IV) compared to older pts (32% Stage III, 26% Stage IV). Associated BRAF mutations were more common in pts > 50 (20% vs. 67%; p = 0.005). Conclusions: In our dataset, younger CRC pts are diagnosed with more advanced disease but with dMMR/MSI-H cancers at the expected rate. However, we identified more (likely sporadic) dMMR/MSI-H stage IV cancers in pts > 50yo than expected. Further studies to identify risk factors for younger patients and the ultimate clinical impact of universal reflex MSI testing is warranted to maximize IO therapy offering and survival.


  • Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management

    by Aaron J. Franke, Hiral Parekh, Jason S. Starr, Sanda A. Tan, Atif Iqbal, Thomas J. George


  • The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma

    by Hiral D. Parekh, Jason Starr, Thomas J. George

    Pancreatic adenocarcinoma 2030 (PCa) is predicted to be the second leading cause of cancer death in USA by 2030. To date, attempts at early detection have been unsuccessful. Therapies for resectable PCa include surgery followed by adjuvant chemotherapy with or without radiotherapy. Unfortunately, most patients with PCa present with advanced disease and thus only 20% of patients are potentially resectable upon presentation. Improved surgical techniques along with adjuvant combination chemotherapy have improved outcomes for patients with resectable disease. The optimal treatment approach for borderline resectable and locally advanced unresectable PCa has not yet been defined. Despite significant advances in the palliative treatment of PCa, long-term survival of early stage disease continues to be sobering. The key to improving outcomes for this largely fatal disease is to identify multidisciplinary therapeutic interventions including surgical, medical, and radiation techniques tailored to the patient and their disease characteristics. The neoadjuvant approach provides an in vivo platform to test novel treatment options to help us understand tumor biology and surrounding microenvironment, which may ultimately help us achieve the goal of improvement in long-term survival. While the neoadjuvant approach remains popular as a way to optimally select patients that might benefit most from surgery, randomized trials utilizing adjuvant and neoadjuvant novel therapies hold the key to truly personalizing the ideal treatment strategy for localized PCa.


  • Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review

    by William Paul Skelton, Hiral Parekh, Jason S. Starr, Jose Trevino, Jessica Cioffi, Steven Hughes, Thomas J. George

    Pancreatic cancer is often diagnosed at late stages, where disease is either locally advanced unresectable or metastatic. Despite advances, long-term survival is relatively non-existent. This review article discusses clinical factors commonly encountered in practice that should be incorporated into the decision-making process to optimize patient outcomes, including performance status, nutrition and cachexia, pain, psychological distress, medical comorbidities, advanced age, and treatment selection. Identification and optimization of these clinical factors could make a meaningful impact on the patient's quality of life.


  • 5-fluorouracil, oxaliplatin and dasatinib (FOLFOX-D) for previously untreated metastatic pancreatic adenocarcinoma.

    by Thomas J. George, Long H. Dang, Karen Colleen Daily, Jason Scott Starr, Hiral D. Parekh, Alison Marguerite Ivey, Daniel Delitto, Carmen Joseph Allegra, Steven J. Hughes, Xiaomin Lu, et al.

    TPS517 Background: Systemic chemotherapy for pancreatic adenocarcinoma improves survival and cancer related symptoms. Most targeted agents combined with gemcitabine have consistently failed to demonstrate clinical benefits. Src is overexpressed in pancreatic cancer and promotes an aggressive cancer phenotype. Dasatinib (D) is an oral multi-tyrosine kinase inhibitor (TKI) affecting tumor proliferation through inhibition of Src, Bcr-Abl, CKit and other pathways. Inhibition of Src is associated with biologic modifications favorably modifying the pancreatic cancer phenotype and has synergy with restoring inherent chemosensitivity. Src inhibition can also increase oxaliplatin activity and modulate Tcell responses. The addition of D to the well-established backbone of FOLFOX represents a multifaceted line of scientific investigation. Methods: This is a multicenter phase II trial to determine activity and toxicity of FOLFOX + D in previously untreated metastatic pancreatic adenocarcinoma. Eligible pts must have at least 1 measurable target lesion by RECIST, ECOG PS 0-2, normal QTc and adequate organ function. Pts received standard cycles of mFOLFOX6 repeated q14d with continuous D (150mg PO daily). Tumor assessments occur q8w. Endpoints included progression-free survival (primary; PFS), objective and biochemical response rates, clinical benefit rate, freedom from metastases, overall survival (OS), toxicity, and quality of life. Exploratory tissue, circulating tumor cell and serum analyses to identify predictors of response are planned, particularly in those demonstrating durable disease control or exceptional response. Sample size was based on a 50% improved median PFS from 4 (historical) to 6 months. NCT01652976. Results: Enrollment continues on this prospective phase II study with 38 of 42 evaluable patients. There are no unexpected toxicities noted thus far. Clinical trial information: NCT01652976. [Table: see text]

  • The effect of routine early palliative care (PC) consultation on aggressiveness of care at the end of life (EOL) in patients with advanced non-small cell lung cancer (NSCLC).

    by Hiral D. Parekh, Katherine Tullio, Paul Elson, Mellar P. Davis, Vamsidhar Velcheti, James Stevenson, Marc A. Shapiro, Cheryl M Carrino, Nathan A. Pennell

    E21688Background: Early integration of PC for patients (pts) with advanced NSCLC improves quality of life, decreases aggressive care at the EOL, and possibly improves survival. In 2011 the Cleveland Clinic instituted routine referral to PC for advanced NSCLC pts at the time of initial assessment. We investigated the real world effects of early PC intervention on aggressiveness of care at the EOL in NSCLC pts before and after this policy. Methods: In a retrospective cohort study, 242 metastatic NSCLC pts cared for at the Cleveland Clinic in 2009-10 (pre-PC) and 2013-14 (post-PC) were reviewed through the tumor registry and electronic medical record. Primary endpoint was % pts receiving aggressive EOL care: chemotherapy within 14 days of death, no hospice care, or admission to hospice 3 days or less before death. Outcomes were also compared in pts who saw PC early ( < 60 days from initial visit) compared to late ( > 60 d) or no PC. Fisher’s exact test was used for factors with 2 levels, chi-square test and ...